FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to infectious diseases and may be used for treating and preventing hepatitis C in an individual received no drug therapy while being infected or at a risk of infection. That is ensured by subcutaneous introduction of mPEG-propionaldehyde pegylated polypeptide 1.5-5.0 mcg/kg having molecular weight approximately 20 kDa. The polypeptide contains the amino acid residues 1-176 SEQ ID NO: 106. and is pegylated type III interferon.
EFFECT: group of inventions provides treating hepatitis C in the above group of patients and reducing the toxic effects of the drugs administered.
11 cl, 113 dwg, 18 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SINGLE NUCLEOTIDE POLYMORPHISM ON CHROMOSOME 15 ENABLING PREDICTION OF HCV TREATMENT RESPONSES | 2012 |
|
RU2606759C2 |
| APPLICATION OF CYCLOSPORINE AND PEGYLATED INTERFERON COMBINATION FOR HEPATITIS (HCV) TREATMENT | 2005 |
|
RU2394589C2 |
| USING POLYETHYLENE GLYCOL-INTERFERON-α (PEG-IFN-α) AND RIBAVIRIN FOR TREATMENT OF CHRONIC HEPATITIS C | 1999 |
|
RU2271217C2 |
| SINGLE NUCLEOTIDE POLYMORPHISMS FOR PREDICTING RESULTS OF TREATMENT OF HEPATIC C VIRUS INFECTION | 2011 |
|
RU2567663C2 |
| SYNTHETIC VERSIONS OF HYPERGLYCOLISED PROTEASE-RESISTIVE POLYPEPTIDE, ORAL COMPOSITIONS AND METHODS OF USING SUCH VERSIONS | 2005 |
|
RU2392963C2 |
| DOSAGE FORMS | 2005 |
|
RU2393863C2 |
| APPLICATION OF MODIFIED CYCLOSPORINS FOR TREATING HCV INDUCED DISEASES | 2004 |
|
RU2389501C2 |
| PEGYLATED INTERFERON LAMBDA WITH HIGH BIOACCESSABILITY IN ORAL USE AND METHOD FOR PRODUCTION THEREOF | 2017 |
|
RU2678332C1 |
| METHOD OF VIRUS INFECTION TREATMENT | 2004 |
|
RU2371195C2 |
| METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTION | 2006 |
|
RU2440822C2 |
